Indivior's 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with ...

Discover how Indivior plans to overcome challenges in the competitive LAI market, drive SUBLOCADE's growth with FDA updates, and achieve long-term ...

Indivior said its revenue outlook was being hampered by weak sales of its film-form medication-assisted therapy for opiate ...

CEO Mark Crossley said the steep fall expected in 2025 net revenue was primarily due to a more than 50% drop at its opiate addiction therapy, Suboxone film, amid intense generic pricing pressures and ...

Indivior swung to a pretax loss of USD43 million for 2024, compared to a profit of USD1 million the previous year, despite an 8.7% rise in net revenue to USD1.19 billion from USD1.09 billion. Diluted ...

(Alliance News) - European stocks opened mixed on Thursday, with the FTSE 100 underperforming, as Russia-Ukraine uncertainty, tariff worries and the possibility of higher for longer interest rates ...